New data for Smith+Nephew’s CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care^* for all time points out to 60 months.^1,2 Read More